<div id="readability-page-1"><p><span>CVS Health (NYSE:CVS - Get Free Report)</span> had its target price lifted by stock analysts at JPMorgan Chase &amp; Co.  from $93.00 to $101.00 in a report issued on Wednesday,MarketScreener reports. The brokerage presently has an &#34;overweight&#34; rating on the pharmacy operator's stock. JPMorgan Chase &amp; Co.'s price target would suggest a potential upside of 29.77% from the stock's current price.</p><ul><li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li></ul><p>Several other equities analysts have also recently commented on the stock. Wolfe Research upped their target price on shares of CVS Health from $85.00 to $100.00 and gave the company an &#34;outperform&#34; rating in a research note on Monday, December 8th. Barclays increased their price objective on shares of CVS Health from $87.00 to $93.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. The Goldman Sachs Group increased their price target on shares of CVS Health from $93.00 to $95.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, December 10th. Morgan Stanley raised their price target on shares of CVS Health from $89.00 to $93.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 10th. Finally, UBS Group  reissued an &#34;outperform&#34; rating on shares of CVS Health in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued  a Hold rating to the company. Based on data from MarketBeat.com, CVS Health currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $94.67.</p><p><b>Check Out Our Latest Report on CVS Health</b></p><h2>CVS Health Price Performance</h2><ul><li>MarketBeat Week in Review – 05/12 - 05/16</li></ul><p>Shares of CVS Health stock opened at $77.83 on Wednesday. CVS Health has a 1-year low of $43.56 and a 1-year high of $85.15. The firm has a fifty day simple moving average of $79.05 and a 200-day simple moving average of $72.20. The company has a current ratio of 0.83, a quick ratio of 0.63 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $98.80 billion, a price-to-earnings ratio of 206.18, a PEG ratio of 0.79 and a beta of 0.48. </p><p>CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping analysts' consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The firm had revenue of $102.87 billion during the quarter, compared to analyst estimates of $98.85 billion. During the same quarter in the previous year, the business earned $1.09 EPS. The business's revenue was up 7.8% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS.  On average, sell-side analysts expect that  CVS Health will post 5.89 earnings per share for the current year. </p><h2>Institutional Investors Weigh In On CVS Health</h2><ul><li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li></ul><p>Large investors have recently bought and sold shares of the business. SOA Wealth Advisors LLC. lifted its holdings in  CVS Health by 36.9% in the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator's stock worth $37,000 after buying an additional 131 shares during the period.  Alteri Wealth LLC lifted its stake in shares of  CVS Health by 3.2% in the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator's stock valued at $316,000 after purchasing an additional 131 shares during the period.  Holistic Financial Partners boosted its position in shares of  CVS Health by 4.1% during the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator's stock valued at $256,000 after purchasing an additional 133 shares in the last quarter.  CYBER HORNET ETFs LLC grew its stake in  CVS Health by 4.1% in the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator's stock worth $259,000 after purchasing an additional 134 shares during the period.  Finally, Fayez Sarofim &amp; Co raised its holdings in  CVS Health by 2.1% in the third quarter. Fayez Sarofim &amp; Co now owns 6,913 shares of the pharmacy operator's stock worth $521,000 after purchasing an additional 140 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors. </p><h2>CVS Health Company Profile</h2> (Get Free Report)<p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p><h2>See Also</h2><ul><li>Five stocks we like better than CVS Health</li><li>P/E Ratio Calculation: How to Assess Stocks</li><li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li><li>Growth Stocks: What They Are, Examples and How to Invest</li><li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li><li>3 Dividend Kings To Consider</li><li>AI Chips Can’t Exist Without These 2 Underrated Tech Giants</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CVS Health Right Now?</h2><p>Before you consider CVS Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>JPMorgan Chase & Co. has raised its price target for CVS Health from $93.00 to $101.00, maintaining an "overweight" rating, suggesting a potential 29.77% upside. Other analysts, including Wolfe Research and Barclays, have also increased their price targets, with CVS Health receiving a consensus "Moderate Buy" rating. The stock opened at $77.83, with a market cap of $98.80 billion. CVS Health reported strong earnings, with a 7.8% revenue increase year-over-year.</p>

JPMorgan Chase & Co. Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price